Economic evaluations of clinical pharmacy services in the United States: 2011-2017

被引:19
|
作者
Talon, Brian [1 ]
Perez, Alexandra [2 ]
Yan, Connie [1 ]
Alobaidi, Ali [1 ]
Zhang, Katherine H. H. [1 ]
Schultz, Bob G. [1 ]
Suda, Katie J. [3 ]
Touchette, Daniel R. [1 ]
机构
[1] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL 60607 USA
[2] Nova Southeastern Univ, Dept Sociobehavioral & Adm Pharm, Ft Lauderdale, FL USA
[3] Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Hlth Care Syst, Dept Med,Sch Med, Pittsburgh, PA USA
关键词
cost-benefit analysis; health services research; pharmacoeconomics; pharmacy; MEDICATION-THERAPY MANAGEMENT; ANTIMICROBIAL STEWARDSHIP PROGRAM; INTENSIVE-CARE-UNIT; ANNUAL WELLNESS VISITS; COST-EFFECTIVENESS; READMISSION RATES; INAPPROPRIATE USE; GLYCEMIC CONTROL; PRACTICE MODEL; DIABETES CARE;
D O I
10.1002/jac5.1199
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Studies evaluating the cost-effectiveness of clinical pharmacy services (CPS) are needed to justify implementation and reimbursement. Through a systematic review, we describe services provided by pharmacists and their economic outcomes. We conducted a literature search of published studies in PubMed, Ovid, and Embase from January 2011 through December 2017. Manuscripts evaluating a CPS with patient-level economic outcomes and conducted in the United States were included. Study risks of bias were classified by study design characteristics. Economic evaluations were classified according to the presence of a comparator, and cost and outcome measures included. The quality of full economic evaluations was assessed using the Quality of Health Economic Studies (QHES) instrument. Descriptive statistics were used to summarize CPS characteristics. After screening, 115 studies were included. Type of service provided included general pharmacotherapy (41%), disease management (30%), and targeted drug program (17%). Settings included hospital (34%), ambulatory care (28%), and community pharmacy (17%). Study designs were considered high risk of bias (use of a historical control group or no control group) in 69% of cases while 25% were medium risk of bias (non-randomized with a concurrent control group) and 6% were low risk of bias (randomized experimental or multigroup interrupted time series). Economic evaluation types were descriptive studies that measured cost and/or outcomes of a CPS (55%), comparative studies that measured cost or outcomes of a CPS and a comparator (37%), and full evaluations that measured cost and outcomes of a CPS and a comparator (8%). Among nine full evaluations, the median (range) QHES score was 74 (59-95) and four reported the CPS as being more effective at a lower cost. Few full economic evaluations were conducted, but supported the cost-effectiveness of CPS. Use of a comparator group and measurement of economic inputs and outcomes would strengthen the body of evidence.
引用
收藏
页码:793 / 806
页数:14
相关论文
共 50 条
  • [1] Psoriasis Prevalence in the United States: 2011-2017
    Cohen, J.
    Wong, P.
    Cohen, D.
    Kim, R.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : B7 - B7
  • [2] Surveillance for Coccidioidomycosis - United States, 2011-2017
    Benedict, Kaitlin
    McCotter, Orion Z.
    Brady, Shane
    Komatsu, Kenneth
    Cooksey, Gail L. Sondermeyer
    Nguyen, Alyssa
    Jain, Seema
    Vugia, Duc J.
    Jackson, Brendan R.
    [J]. MMWR SURVEILLANCE SUMMARIES, 2019, 68 (07): : 1 - 15
  • [3] Patterns of TB transmission in the United States, 2011-2017
    Yamkovoy, K.
    Self, J. L.
    Jenkins, H. E.
    Horsburgh, C. R.
    White, L. F.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2024, 28 (03) : 154 - 156
  • [4] The changing landscape of naloxone availability in the United States, 2011-2017
    Freeman, Patricia R.
    Hankosky, Emily R.
    Lofwall, Michelle R.
    Talbert, Jeffery C.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2018, 191 : 361 - 364
  • [5] Prevalence and Incidence of Obesity and Diabetes in the United States, 2011-2017
    Nielsen, Jannie
    Gregg, Ed
    Narayan, K. M. Venkat
    Cunningham, Solveig A.
    [J]. DIABETES, 2020, 69
  • [6] Improving the quality of economic evaluations of clinical pharmacy services
    Touchette, Daniel R.
    Perez, Alexandra
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2023, 6 (06): : 565 - 569
  • [7] Measles Hospitalizations at a United States Children's Hospital 2011-2017
    Hester, Gabrielle
    Nickel, Amanda
    LeBlanc, Julie
    Carlson, Rebecca
    Spaulding, Alicen B.
    Kalaskar, Anupama
    Stinchfield, Patricia
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (06) : 547 - 552
  • [8] CLINICAL PHARMACY SERVICES IN THE UNITED-STATES
    RAY, MD
    [J]. PHARMACY INTERNATIONAL, 1980, 1 (04): : R8 - R9
  • [9] Economic evaluations of clinical pharmacy services: 2006-2010.
    Touchette, Daniel R.
    Doloresco, Fred
    Suda, Katie J.
    Perez, Alexandra
    Turner, Stuart
    Jalundhwala, Yash J.
    Tangonan, Maria C.
    Hoffman, James M.
    [J]. PHARMACOTHERAPY, 2012, 32 (10): : E231 - E231
  • [10] Economic evaluations of clinical pharmacy services - 1988-1995
    Schumock, GT
    Meek, PD
    Ploetz, PA
    Vermeulen, LC
    Alldredge, B
    Amsden, G
    Anderson, D
    Bednarczyk, E
    Goodwin, SD
    Jaber, L
    Knoppert, D
    Mueller, B
    Otto, M
    Poirier, T
    Rho, J
    Scheife, R
    Smythe, M
    Thomas, W
    Thompson, D
    Uden, D
    Vasquez, E
    [J]. PHARMACOTHERAPY, 1996, 16 (06): : 1188 - 1208